Darlene Dobkowski, MA

Join us for an Educated Patient® Webinar to explore the essential aspects of radiotherapy as a treatment for cancer, in addition to its various types and practical advice on managing side effects.

The FDA will review an application for Cabometyx as a potential treatment for pancreatic neuroendocrine tumors after findings from a phase 3 trial.

Actress Shannen Doherty has been open about her experience with breast cancer over the last few years as a way to help other people.

Increased awareness and support may be one of the many ways to help decrease the impact of disparities in multiple myeloma.

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

During this in-person event, over 500 attendees celebrated the remarkable efforts made by oncology nurses in the care of patients with cancer.

In collaboration with the Kidney Cancer Association, CURE® recently hosted the “Educated Patient® Webinar: Treating the Whole Patient: Navigating Kidney Cancer,” hosted by Darlene Dobkowski, Associate Editorial Director for CURE®.

During the CURE Educated Patient® Breast Cancer Summit, an expert discussed her professional and personal experience with side effect management in metastatic breast cancer.

A patient advocate and oncology nurse discuss the importance of physical and mental health during the breast cancer journey during a panel session at the CURE® Educated Patient® Breast Cancer Summit.

An oncology nurse discusses how virtual reality can be used to educate patients and decrease stress before treatment or while in palliative care.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

A 2.5-mg dose of olanzapine provided similar control of nausea/vomiting as the standard 10-milligram dose in patients with solid tumors receiving chemotherapy.

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

This study assessed the impact of laughter therapy in both patients with cancer and caregivers, and both groups showed decreases in mood disturbances, in addition to decreases in pain for patients and in burnout for caregivers.

The use of the chemotherapy regimen FOLFOXIRI plus Avastin has increased from 2013 to 2022 in patients with metastatic colorectal cancer, particularly in patients aged 50 years and younger.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

The pharmaceutical company submitted applications for the FDA to consider approval of Rybrevant plus lazertinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858 substitution mutations.

Diet and exercise can benefit patients with cancer through side effect management and improved outcomes. CURE provides an overview of the most-read diet and exercise stories of 2023.

The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.

CURE shares the top stories in breast cancer, which focus on topics like treatment decisions, feelings on awareness months and books focused on breast reconstruction.

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing.

An expert discussed the importance of knowing the questions to ask a patient’s care team to navigate one’s journey, including treatment and next steps.

An expert explained how ableism is present in cancer care, including chemotherapy eligibility, and how more awareness is needed in this space.

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

Autologous hematopoietic cell transplantation, compared with CAR-T cell therapy, resulted in lower rates of relapse and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

CURE® honored eight MPN Heroes, which ranged from medical professionals to patients and caregivers, on the contributions they made in the field.

The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

The FDA recently approved Tibsovo for relapsed/refractory MDS with an IDH1 mutation, a treatment option for a disease subset with no options before this approval.